Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.
Zhong YuanBennett LevitanHsiaowei DengMichael SzarekRupert M BauersachsScott D BerkowitzLloyd P HaskellElliot S BarnathanMarc P BonacaPublished in: Journal of the American Heart Association (2024)
These analyses show a favorable benefit-risk profile of rivaroxaban therapy in the VOYAGER PAD trial, with findings generally consistent between the unweighted and weighted approaches.
Keyphrases
- venous thromboembolism
- atrial fibrillation
- study protocol
- end stage renal disease
- phase iii
- clinical trial
- ejection fraction
- pulmonary embolism
- newly diagnosed
- magnetic resonance
- prognostic factors
- randomized controlled trial
- stem cells
- coronary artery bypass grafting
- acute coronary syndrome
- smoking cessation
- breast cancer risk